Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics, Inc. appointed Liisa Bayko as Chief Financial Officer, Treasurer and principal financial officer effective July 20, 2026. Her Employment Agreement provides a base salary of $475,000, eligibility for an annual bonus of up to 40.0% of base salary, and standard non‑competition, non‑solicitation and confidentiality covenants.
Bayko received an incentive stock option to purchase 220,000 shares of common stock, with an exercise price set at the Nasdaq closing price on the effective date. The option vests 25% on the first anniversary of her start date and monthly over 36 months thereafter, subject to continued service. If terminated without cause or for good reason outside a change in control window, she may receive nine months of base salary and COBRA premium support; this increases to 12 months of salary, a bonus equal to 100% of target, extended COBRA premium support and full time‑based equity vesting if such a termination occurs in proximity to a change in control.
Brett Hagen resigned as Senior Vice President, Finance and Chief Accounting Officer effective July 27, 2026. The Board designated Amy Vandekop, Corporate Controller, as interim principal accounting officer effective the same date, with no changes to her existing compensation arrangements. Both Bayko and Vandekop entered into indemnification agreements covering certain legal expenses arising from their service as officers.
Kalaris Therapeutics reported positive additional data from its expanded Phase 1a single ascending dose trial of TH103 in treatment-naïve neovascular age-related macular degeneration. The dataset now covers 17 treatment-naïve and 3 treatment-experienced patients, all followed for six months, and continues to show robust structural and functional vision improvements.
TH103 demonstrated pharmacokinetics suggesting extended intraocular retention, with 27- to 53-fold lower plasma Cmax than leading anti-VEGF agents on a molar basis. After a single injection, 41% of treatment-naïve patients were retreated at four months or later and 29% needed no additional anti-VEGF therapy over six months; treatment-experienced patients saw an average two‑month extension in retreatment intervals. No intraocular inflammation occurred in six patients at the 2.5 mg dose produced with an improved process, while one prior 5 mg patient had transient inflammation that resolved. Kalaris is enrolling a Phase 1b/2 multiple-ascending dose study using a four-dose loading regimen in treatment-naïve patients and remains on track to share initial data in the first half of 2027; investor materials also indicate cash runway into Q4 2027.
Kalaris Therapeutics reported a board change and related director compensation. Morana Jovan-Embiricos, Ph.D., resigned from the board and the Audit Committee, and stated her resignation was not due to any disagreement with the company’s operations, policies or practices.
The board elected Laurie Keating as a Class I director, effective August 1, 2026, with a term running to the 2027 annual meeting. She will also join the Audit Committee. As a non-employee director, she will receive an option for 18,000 shares vesting over three years, annual cash fees for board and committee service, ongoing equity grants under the director compensation policy and standard indemnification protection.
Kalaris Therapeutics director Jovan-Embiricos Morana received a stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.7200 per share and expires on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service. Following this grant, Morana holds options to purchase 9,000 shares directly.
Kalaris Therapeutics, Inc. director Ferrara Napoleone received a grant of stock options covering 9,000 shares of common stock. The options have an exercise price of $4.7200 per share and expire on June 2, 2036. The 9,000 underlying shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service.
Kalaris Therapeutics director David Hallal received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and was granted as compensation rather than a market purchase.
The option was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, conditioned on his continued service. Following this grant, Hallal holds options for 9,000 underlying shares directly.
Kalaris Therapeutics director Srinivas Akkaraju received a grant of options to buy 9,000 shares of common stock on June 3, 2026. The options have an exercise price of $4.72 per share and expire on June 2, 2036. The underlying 9,000 shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to continued service. After this grant, the filing shows Akkaraju holding 9,000 stock options directly.
Kalaris Therapeutics, Inc. director Michael Dybbs received a grant of stock options representing 9,000 shares of Common Stock. The options have an exercise price of $4.72 per share and expire on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics' 2027 Annual Meeting of Stockholders, provided he continues to serve the company through that time. Following this grant, he holds 9,000 derivative securities directly.
Kalaris Therapeutics director Anthony P. Adamis received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and expires on June 2, 2036.
The shares underlying the option are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, subject to continued service. Following this grant, Adamis holds 9,000 derivative securities linked to common stock directly.
Kalaris Therapeutics director Leone D. Patterson received a new stock option grant covering 9,000 shares of common stock. The option has an exercise price of $4.72 per share and increases her directly held option position to 9,000 shares. The award was granted on June 3, 2026 and is scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues in service.